AgomAb Therapeutics N.V. American Depositary Shares Intangible Assets

AgomAb Therapeutics N.V. American Depositary Shares posts a intangible assets of $20M as of June 2026. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

Intangible Assets is one piece of AgomAb Therapeutics N.V. American Depositary Shares's financial statement story. At $20M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for AGMB's intangible assets usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; AgomAb Therapeutics N.V. American Depositary Shares's other metric pages and overview cover the third.

Judging AgomAb Therapeutics N.V. American Depositary Shares against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in intangible assets easier to interpret. Start with $20M here, then scan peer and history charts to see if the gap is persistent.